Retour

QIAGEN übertrifft Prognosen für das erste Quartal 2024 und bleibt auf Kurs, die Jahresziele 2024 zu erreichen

Stocks Earnings Releases and Operating Results

Q1 2024: Konzernumsatz von $459 Mio. (-5% bei tatsächlichen Kursen; -5% bei konstanten Wechselkursen, CER); verwässerter Gewinn je Aktie von $0,36; bereinigter verwässerter Gewinn je Aktie von $0,46 // Konzernumsatz bei konstanten Wechselkursen (CER) von $462 Mio. übertrifft Prognose von mindestens $455 Mio. (CER); bereinigter verwässerter Gewinn je Aktie von $0,47 (CER) übertrifft Prognose von mindestens $0,44 CER // Ohne COVID-Produktgruppen sinkt Umsatz um 1% (CER) // Diagnostik-Umsätze steigen um 5% CER aufgrund zweistelliger CER-Zuwächse bei QuantiFERON und QIAstat-Dx // Bereinigte operative Marge steigt aufgrund von Effizienzsteigerungen von 25,6% (Q1 2023) auf 25,7% // Starker operativer Cashflow steigt im Vergleich zu Q1 2023 um 85% auf $133 Mio. // Prognose für 2024 bekräftigt: Konzernumsatz von mindestens $2,0 Mrd. (CER); bereinigter verwässerter Gewinn je Aktie von mindestens $2,10 (CER)

GlobeNewswire Inc. • 29/04/2024 à 22:05:00
QIAGEN N.V.
Website: https://www.qiagen.com
Status: Active
Company Info

Qiagen NV offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).

List Date1996-06-28
MarketStocks
LocalUS
Primary ExchangeXNYS
TypeCS
Currency NameUSD
CIK0001015820
Market Cap9,674,747,670 USD
Total Employees5900
Share Class Shares Outstanding221360000
Weighted Shares Outstanding221847000
Round Lot100
Updated date2024-05-12
Stats
Last 5 days
15-05
14-05
13-05
10-05
9-05
Last
45.775
45.375
44.34
43.61
43.59
Variance
0.85%
2.34%
1.56%
0.05%
1.4%
Open
45.39
44.338
43.661
43.588
42.987
Highest
45.785
45.391
44.404
44.033
43.715
Lowest
45.777
45.375
44.385
44.02
43.695
History
PeriodVarhighestlowest
1 week
6.99%
43.715
43.695
1 month
17.21%
41.43
39.701
3 month
7.2%
43.41
39.701
6 month
12.87%
40.8478
39.701
1 year
-1.38%
46.7672
35.8256
3 year
-5.15%
48.7988
35.8256
5 year
18.45%
39.0328
25.8225
10 year
91.8%
24.1919
21.354
Calendar
16 May 2024 (Time UTC) Actual Previous Consensus
★
16:30
United States
3331000000000.000
★★
16:30
United States
7353000000000.000
★
15:50
United States
★★
11:30
United States
★
11:30
United States
5.270
5.275
★
11:30
United States
5.270
5.270
★
11:30
United States
★
11:30
United States
★★
10:30
United States
★
10:30
United States
MAY 10
70000000000.000
79000000000.000
76000000000.000
★
10:30
United States
MAY 10
★★
10:00
United States
★
09:15
United States
APR
-0.300
0.200
0.100
★★
09:15
United States
APR
-0.380
0.090
★
09:15
United States
APR
78.400
78.500
78.400
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:QGEN240419P00065000 OPASPS Put American 100 65 BATO 2024-04-19
O:QGEN240419P00060000 OPASPS Put American 100 60 BATO 2024-04-19
O:QGEN240419P00055000 OPASPS Put American 100 55 BATO 2024-04-19
O:QGEN240419P00050000 OPASPS Put American 100 50 BATO 2024-04-19
O:QGEN240419P00045000 OPASPS Put American 100 45 BATO 2024-04-19
O:QGEN240419P00040000 OPASPS Put American 100 40 BATO 2024-04-19
O:QGEN240419P00035000 OPASPS Put American 100 35 BATO 2024-04-19
O:QGEN240419P00030000 OPASPS Put American 100 30 BATO 2024-04-19
O:QGEN240419P00025000 OPASPS Put American 100 25 BATO 2024-04-19
O:QGEN240419C00065000 OCASPS Call American 100 65 BATO 2024-04-19
O:QGEN240419C00060000 OCASPS Call American 100 60 BATO 2024-04-19
O:QGEN240419C00055000 OCASPS Call American 100 55 BATO 2024-04-19
O:QGEN240419C00050000 OCASPS Call American 100 50 BATO 2024-04-19
O:QGEN240419C00045000 OCASPS Call American 100 45 BATO 2024-04-19
O:QGEN240419C00040000 OCASPS Call American 100 40 BATO 2024-04-19
O:QGEN240419C00035000 OCASPS Call American 100 35 BATO 2024-04-19
O:QGEN240419C00030000 OCASPS Call American 100 30 BATO 2024-04-19
O:QGEN240419C00025000 OCASPS Call American 100 25 BATO 2024-04-19
O:QGEN1240419P00065000 OPASPN Put American 97 65 BATO 2024-04-19
O:QGEN1240419P00060000 OPASPN Put American 97 60 BATO 2024-04-19
O:QGEN1240419P00055000 OPASPN Put American 97 55 BATO 2024-04-19
O:QGEN1240419P00050000 OPASPN Put American 97 50 BATO 2024-04-19
O:QGEN1240419P00045000 OPASPN Put American 97 45 BATO 2024-04-19
O:QGEN1240419P00040000 OPASPN Put American 97 40 BATO 2024-04-19
O:QGEN1240419P00035000 OPASPN Put American 97 35 BATO 2024-04-19
O:QGEN1240419P00030000 OPASPN Put American 97 30 BATO 2024-04-19
O:QGEN1240419P00025000 OPASPN Put American 97 25 BATO 2024-04-19
O:QGEN1240419P00022500 OPASPN Put American 97 22.5 BATO 2024-04-19
O:QGEN1240419C00065000 OCASPN Call American 97 65 BATO 2024-04-19
O:QGEN1240419C00060000 OCASPN Call American 97 60 BATO 2024-04-19
O:QGEN1240419C00055000 OCASPN Call American 97 55 BATO 2024-04-19
O:QGEN1240419C00050000 OCASPN Call American 97 50 BATO 2024-04-19
O:QGEN1240419C00045000 OCASPN Call American 97 45 BATO 2024-04-19
O:QGEN1240419C00040000 OCASPN Call American 97 40 BATO 2024-04-19
O:QGEN1240419C00035000 OCASPN Call American 97 35 BATO 2024-04-19
O:QGEN1240419C00030000 OCASPN Call American 97 30 BATO 2024-04-19
O:QGEN240419P00022500 OPASPS Put American 100 22.5 BATO 2024-04-19
O:QGEN1240419C00025000 OCASPN Call American 97 25 BATO 2024-04-19
O:QGEN240419C00022500 OCASPS Call American 100 22.5 BATO 2024-04-19
O:QGEN1240419C00022500 OCASPN Call American 97 22.5 BATO 2024-04-19
O:QGEN1240315P00065000 OPASPN Put American 97 65 BATO 2024-03-15
O:QGEN1240315P00060000 OPASPN Put American 97 60 BATO 2024-03-15
O:QGEN1240315P00055000 OPASPN Put American 97 55 BATO 2024-03-15
O:QGEN1240315P00050000 OPASPN Put American 97 50 BATO 2024-03-15
O:QGEN1240315P00045000 OPASPN Put American 97 45 BATO 2024-03-15
O:QGEN1240315P00040000 OPASPN Put American 97 40 BATO 2024-03-15
O:QGEN1240315P00035000 OPASPN Put American 97 35 BATO 2024-03-15
O:QGEN1240315P00030000 OPASPN Put American 97 30 BATO 2024-03-15
O:QGEN1240315P00025000 OPASPN Put American 97 25 BATO 2024-03-15
O:QGEN1240315P00022500 OPASPN Put American 97 22.5 BATO 2024-03-15
O:QGEN1240315C00065000 OCASPN Call American 97 65 BATO 2024-03-15
O:QGEN1240315C00060000 OCASPN Call American 97 60 BATO 2024-03-15
O:QGEN1240315C00055000 OCASPN Call American 97 55 BATO 2024-03-15
O:QGEN1240315C00050000 OCASPN Call American 97 50 BATO 2024-03-15
O:QGEN1240315C00045000 OCASPN Call American 97 45 BATO 2024-03-15
O:QGEN1240315C00040000 OCASPN Call American 97 40 BATO 2024-03-15
O:QGEN1240315C00035000 OCASPN Call American 97 35 BATO 2024-03-15
O:QGEN1240315C00030000 OCASPN Call American 97 30 BATO 2024-03-15
O:QGEN1240315C00025000 OCASPN Call American 97 25 BATO 2024-03-15
O:QGEN1240315C00022500 OCASPN Call American 97 22.5 BATO 2024-03-15
O:QGEN240315P00065000 OPASPS Put American 100 65 BATO 2024-03-15
O:QGEN240315P00060000 OPASPS Put American 100 60 BATO 2024-03-15
O:QGEN240315P00055000 OPASPS Put American 100 55 BATO 2024-03-15
O:QGEN240315P00050000 OPASPS Put American 100 50 BATO 2024-03-15
O:QGEN240315P00045000 OPASPS Put American 100 45 BATO 2024-03-15
O:QGEN240315P00040000 OPASPS Put American 100 40 BATO 2024-03-15
O:QGEN240315P00035000 OPASPS Put American 100 35 BATO 2024-03-15
O:QGEN240315P00030000 OPASPS Put American 100 30 BATO 2024-03-15
O:QGEN240315P00025000 OPASPS Put American 100 25 BATO 2024-03-15
O:QGEN240315P00022500 OPASPS Put American 100 22.5 BATO 2024-03-15
O:QGEN240315C00065000 OCASPS Call American 100 65 BATO 2024-03-15
O:QGEN240315C00060000 OCASPS Call American 100 60 BATO 2024-03-15
O:QGEN240315C00055000 OCASPS Call American 100 55 BATO 2024-03-15
O:QGEN240315C00050000 OCASPS Call American 100 50 BATO 2024-03-15
O:QGEN240315C00045000 OCASPS Call American 100 45 BATO 2024-03-15
O:QGEN240315C00040000 OCASPS Call American 100 40 BATO 2024-03-15
O:QGEN240315C00035000 OCASPS Call American 100 35 BATO 2024-03-15
O:QGEN240315C00030000 OCASPS Call American 100 30 BATO 2024-03-15
O:QGEN240315C00025000 OCASPS Call American 100 25 BATO 2024-03-15
O:QGEN240315C00022500 OCASPS Call American 100 22.5 BATO 2024-03-15
O:QGEN240216P00022500 OPASPS Put American 100 22.5 BATO 2024-02-16
O:QGEN240216C00022500 OCASPS Call American 100 22.5 BATO 2024-02-16
O:QGEN240216P00065000 OPASPS Put American 100 65 BATO 2024-02-16
O:QGEN240216P00060000 OPASPS Put American 100 60 BATO 2024-02-16
O:QGEN240216P00055000 OPASPS Put American 100 55 BATO 2024-02-16
O:QGEN240216P00050000 OPASPS Put American 100 50 BATO 2024-02-16
O:QGEN240216P00045000 OPASPS Put American 100 45 BATO 2024-02-16
O:QGEN240216P00040000 OPASPS Put American 100 40 BATO 2024-02-16
O:QGEN240216P00035000 OPASPS Put American 100 35 BATO 2024-02-16
O:QGEN240216P00030000 OPASPS Put American 100 30 BATO 2024-02-16
O:QGEN240216P00025000 OPASPS Put American 100 25 BATO 2024-02-16
O:QGEN240216C00065000 OCASPS Call American 100 65 BATO 2024-02-16
O:QGEN240216C00060000 OCASPS Call American 100 60 BATO 2024-02-16
O:QGEN240216C00055000 OCASPS Call American 100 55 BATO 2024-02-16
O:QGEN240216C00050000 OCASPS Call American 100 50 BATO 2024-02-16
O:QGEN240216C00045000 OCASPS Call American 100 45 BATO 2024-02-16
O:QGEN240216C00040000 OCASPS Call American 100 40 BATO 2024-02-16
O:QGEN240216C00035000 OCASPS Call American 100 35 BATO 2024-02-16
O:QGEN240216C00030000 OCASPS Call American 100 30 BATO 2024-02-16
O:QGEN240216C00025000 OCASPS Call American 100 25 BATO 2024-02-16
O:QGEN240119P00070000 OPASPS Put American 100 70 BATO 2024-01-19
O:QGEN240119P00065000 OPASPS Put American 100 65 BATO 2024-01-19
O:QGEN240119P00060000 OPASPS Put American 100 60 BATO 2024-01-19
O:QGEN240119P00055000 OPASPS Put American 100 55 BATO 2024-01-19
O:QGEN240119P00050000 OPASPS Put American 100 50 BATO 2024-01-19
O:QGEN240119P00045000 OPASPS Put American 100 45 BATO 2024-01-19
O:QGEN240119P00040000 OPASPS Put American 100 40 BATO 2024-01-19
O:QGEN240119P00035000 OPASPS Put American 100 35 BATO 2024-01-19
O:QGEN240119P00030000 OPASPS Put American 100 30 BATO 2024-01-19
O:QGEN240119P00025000 OPASPS Put American 100 25 BATO 2024-01-19
O:QGEN240119C00070000 OCASPS Call American 100 70 BATO 2024-01-19
O:QGEN240119C00065000 OCASPS Call American 100 65 BATO 2024-01-19
O:QGEN240119C00060000 OCASPS Call American 100 60 BATO 2024-01-19
O:QGEN240119C00055000 OCASPS Call American 100 55 BATO 2024-01-19
O:QGEN240119C00050000 OCASPS Call American 100 50 BATO 2024-01-19
O:QGEN240119C00045000 OCASPS Call American 100 45 BATO 2024-01-19
O:QGEN240119C00040000 OCASPS Call American 100 40 BATO 2024-01-19
O:QGEN240119C00035000 OCASPS Call American 100 35 BATO 2024-01-19
O:QGEN240119C00030000 OCASPS Call American 100 30 BATO 2024-01-19
O:QGEN240119C00025000 OCASPS Call American 100 25 BATO 2024-01-19
O:QGEN240119P00022500 OPASPS Put American 100 22.5 BATO 2024-01-19
O:QGEN240119P00020000 OPASPS Put American 100 20 BATO 2024-01-19
O:QGEN240119C00022500 OCASPS Call American 100 22.5 BATO 2024-01-19
O:QGEN240119C00020000 OCASPS Call American 100 20 BATO 2024-01-19
O:QGEN231215C00040000 OCASPS Call American 100 40 BATO 2023-12-15
O:QGEN231215C00035000 OCASPS Call American 100 35 BATO 2023-12-15
O:QGEN231215C00030000 OCASPS Call American 100 30 BATO 2023-12-15
O:QGEN231215C00025000 OCASPS Call American 100 25 BATO 2023-12-15
O:QGEN231215P00022500 OPASPS Put American 100 22.5 BATO 2023-12-15
O:QGEN231215P00020000 OPASPS Put American 100 20 BATO 2023-12-15
O:QGEN231215C00022500 OCASPS Call American 100 22.5 BATO 2023-12-15
O:QGEN231215C00020000 OCASPS Call American 100 20 BATO 2023-12-15
O:QGEN231215P00070000 OPASPS Put American 100 70 BATO 2023-12-15
O:QGEN231215P00065000 OPASPS Put American 100 65 BATO 2023-12-15
O:QGEN231215P00060000 OPASPS Put American 100 60 BATO 2023-12-15
O:QGEN231215P00055000 OPASPS Put American 100 55 BATO 2023-12-15
O:QGEN231215P00050000 OPASPS Put American 100 50 BATO 2023-12-15
O:QGEN231215P00045000 OPASPS Put American 100 45 BATO 2023-12-15
O:QGEN231215P00040000 OPASPS Put American 100 40 BATO 2023-12-15
O:QGEN231215P00035000 OPASPS Put American 100 35 BATO 2023-12-15
O:QGEN231215P00030000 OPASPS Put American 100 30 BATO 2023-12-15
O:QGEN231215P00025000 OPASPS Put American 100 25 BATO 2023-12-15
O:QGEN231215C00070000 OCASPS Call American 100 70 BATO 2023-12-15
O:QGEN231215C00065000 OCASPS Call American 100 65 BATO 2023-12-15
O:QGEN231215C00060000 OCASPS Call American 100 60 BATO 2023-12-15
O:QGEN231215C00055000 OCASPS Call American 100 55 BATO 2023-12-15
O:QGEN231215C00050000 OCASPS Call American 100 50 BATO 2023-12-15
O:QGEN231215C00045000 OCASPS Call American 100 45 BATO 2023-12-15
O:QGEN231117P00075000 OPASPS Put American 100 75 BATO 2023-11-17
O:QGEN231117P00070000 OPASPS Put American 100 70 BATO 2023-11-17
O:QGEN231117P00065000 OPASPS Put American 100 65 BATO 2023-11-17
O:QGEN231117P00060000 OPASPS Put American 100 60 BATO 2023-11-17
O:QGEN231117P00055000 OPASPS Put American 100 55 BATO 2023-11-17
O:QGEN231117P00050000 OPASPS Put American 100 50 BATO 2023-11-17
O:QGEN231117P00045000 OPASPS Put American 100 45 BATO 2023-11-17
O:QGEN231117P00040000 OPASPS Put American 100 40 BATO 2023-11-17
O:QGEN231117P00035000 OPASPS Put American 100 35 BATO 2023-11-17
O:QGEN231117P00030000 OPASPS Put American 100 30 BATO 2023-11-17
O:QGEN231117P00025000 OPASPS Put American 100 25 BATO 2023-11-17
O:QGEN231117C00075000 OCASPS Call American 100 75 BATO 2023-11-17
O:QGEN231117C00070000 OCASPS Call American 100 70 BATO 2023-11-17
O:QGEN231117C00065000 OCASPS Call American 100 65 BATO 2023-11-17
O:QGEN231117C00060000 OCASPS Call American 100 60 BATO 2023-11-17
O:QGEN231117C00055000 OCASPS Call American 100 55 BATO 2023-11-17
O:QGEN231117C00050000 OCASPS Call American 100 50 BATO 2023-11-17
O:QGEN231117C00045000 OCASPS Call American 100 45 BATO 2023-11-17
O:QGEN231117C00040000 OCASPS Call American 100 40 BATO 2023-11-17
O:QGEN231117C00035000 OCASPS Call American 100 35 BATO 2023-11-17
O:QGEN231117C00030000 OCASPS Call American 100 30 BATO 2023-11-17
O:QGEN231117C00025000 OCASPS Call American 100 25 BATO 2023-11-17
O:QGEN231020P00075000 OPASPS Put American 100 75 BATO 2023-10-20
O:QGEN231020P00070000 OPASPS Put American 100 70 BATO 2023-10-20
O:QGEN231020P00065000 OPASPS Put American 100 65 BATO 2023-10-20
O:QGEN231020P00060000 OPASPS Put American 100 60 BATO 2023-10-20
O:QGEN231020P00055000 OPASPS Put American 100 55 BATO 2023-10-20
O:QGEN231020P00050000 OPASPS Put American 100 50 BATO 2023-10-20
O:QGEN231020P00045000 OPASPS Put American 100 45 BATO 2023-10-20
O:QGEN231020P00040000 OPASPS Put American 100 40 BATO 2023-10-20
O:QGEN231020P00035000 OPASPS Put American 100 35 BATO 2023-10-20
O:QGEN231020P00030000 OPASPS Put American 100 30 BATO 2023-10-20
O:QGEN231020P00025000 OPASPS Put American 100 25 BATO 2023-10-20
O:QGEN231020P00022500 OPASPS Put American 100 22.5 BATO 2023-10-20
O:QGEN231020C00075000 OCASPS Call American 100 75 BATO 2023-10-20
O:QGEN231020C00070000 OCASPS Call American 100 70 BATO 2023-10-20
O:QGEN231020C00065000 OCASPS Call American 100 65 BATO 2023-10-20
O:QGEN231020C00060000 OCASPS Call American 100 60 BATO 2023-10-20
O:QGEN231020C00055000 OCASPS Call American 100 55 BATO 2023-10-20
O:QGEN231020C00050000 OCASPS Call American 100 50 BATO 2023-10-20
O:QGEN231020C00045000 OCASPS Call American 100 45 BATO 2023-10-20
O:QGEN231020C00040000 OCASPS Call American 100 40 BATO 2023-10-20
O:QGEN231020C00035000 OCASPS Call American 100 35 BATO 2023-10-20
O:QGEN231020C00030000 OCASPS Call American 100 30 BATO 2023-10-20
O:QGEN231020C00025000 OCASPS Call American 100 25 BATO 2023-10-20
O:QGEN231020C00022500 OCASPS Call American 100 22.5 BATO 2023-10-20
O:QGEN230915P00070000 OPASPS Put American 100 70 BATO 2023-09-15
O:QGEN230915P00065000 OPASPS Put American 100 65 BATO 2023-09-15
O:QGEN230915P00060000 OPASPS Put American 100 60 BATO 2023-09-15
O:QGEN230915P00055000 OPASPS Put American 100 55 BATO 2023-09-15
O:QGEN230915P00050000 OPASPS Put American 100 50 BATO 2023-09-15
O:QGEN230915P00045000 OPASPS Put American 100 45 BATO 2023-09-15
O:QGEN230915P00040000 OPASPS Put American 100 40 BATO 2023-09-15
O:QGEN230915P00035000 OPASPS Put American 100 35 BATO 2023-09-15
O:QGEN230915P00030000 OPASPS Put American 100 30 BATO 2023-09-15
O:QGEN230915P00025000 OPASPS Put American 100 25 BATO 2023-09-15
O:QGEN230915C00070000 OCASPS Call American 100 70 BATO 2023-09-15
O:QGEN230915C00065000 OCASPS Call American 100 65 BATO 2023-09-15
O:QGEN230915C00060000 OCASPS Call American 100 60 BATO 2023-09-15
O:QGEN230915C00055000 OCASPS Call American 100 55 BATO 2023-09-15
O:QGEN230915C00050000 OCASPS Call American 100 50 BATO 2023-09-15
O:QGEN230915C00045000 OCASPS Call American 100 45 BATO 2023-09-15
O:QGEN230915C00040000 OCASPS Call American 100 40 BATO 2023-09-15
O:QGEN230915C00035000 OCASPS Call American 100 35 BATO 2023-09-15
O:QGEN230915C00030000 OCASPS Call American 100 30 BATO 2023-09-15
O:QGEN230915C00025000 OCASPS Call American 100 25 BATO 2023-09-15
O:QGEN230818P00075000 OPASPS Put American 100 75 BATO 2023-08-18
O:QGEN230818P00070000 OPASPS Put American 100 70 BATO 2023-08-18
O:QGEN230818P00065000 OPASPS Put American 100 65 BATO 2023-08-18
O:QGEN230818P00060000 OPASPS Put American 100 60 BATO 2023-08-18
O:QGEN230818P00055000 OPASPS Put American 100 55 BATO 2023-08-18
O:QGEN230818P00050000 OPASPS Put American 100 50 BATO 2023-08-18
O:QGEN230818P00045000 OPASPS Put American 100 45 BATO 2023-08-18
O:QGEN230818P00040000 OPASPS Put American 100 40 BATO 2023-08-18
O:QGEN230818P00035000 OPASPS Put American 100 35 BATO 2023-08-18
O:QGEN230818P00030000 OPASPS Put American 100 30 BATO 2023-08-18
O:QGEN230818P00025000 OPASPS Put American 100 25 BATO 2023-08-18
O:QGEN230818C00075000 OCASPS Call American 100 75 BATO 2023-08-18
O:QGEN230818C00070000 OCASPS Call American 100 70 BATO 2023-08-18
O:QGEN230818C00065000 OCASPS Call American 100 65 BATO 2023-08-18
O:QGEN230818C00060000 OCASPS Call American 100 60 BATO 2023-08-18
O:QGEN230818C00055000 OCASPS Call American 100 55 BATO 2023-08-18
O:QGEN230818C00050000 OCASPS Call American 100 50 BATO 2023-08-18
O:QGEN230818C00045000 OCASPS Call American 100 45 BATO 2023-08-18
O:QGEN230818C00040000 OCASPS Call American 100 40 BATO 2023-08-18
O:QGEN230818C00035000 OCASPS Call American 100 35 BATO 2023-08-18
O:QGEN230818C00030000 OCASPS Call American 100 30 BATO 2023-08-18
O:QGEN230818C00025000 OCASPS Call American 100 25 BATO 2023-08-18
News Stream
Stocks Company Announcement
QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support
As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use // Regulatory framework ensures greater patient protection, transparency of information, and traceability of data // Over 4 million NGS patient test cases for oncology and hereditary diseases worldwide processed with QIAGEN Clinical Insight Interpret As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use // Regulatory framework ensures greater patient protection, transparency of information, and traceability of data // Over 4 million NGS patient test cases for oncology and hereditary diseases worldwide processed with QIAGEN Clinical Insight Interpret
GlobeNewswire Inc. • 2d ago
News Product / Services Announcement
QIAGEN erhält europäische IVDR-Zertifizierung für seine Medizinprodukte-Software zur Unterstützung der klinischen Entscheidungsfindung QIAGEN Clinical Insight Interpret
Aktualisierte Version von QIAGEN Clinical Insight Interpret als erste NGS-Interpretationsplattform für Onkologie und Erbkrankheiten für den Einsatz in der Diagnostik zugelassen // Rechtsrahmen stellt besseren Patientenschutz, transparente Informationen und Nachverfolgbarkeit von Daten sicher // Weltweit über 4 Millionen NGS-Patiententests in den Bereichen Onkologie und Erbkrankheiten mit QIAGEN Clinical Insight Interpret durchgeführt Aktualisierte Version von QIAGEN Clinical Insight Interpret als erste NGS-Interpretationsplattform für Onkologie und Erbkrankheiten für den Einsatz in der Diagnostik zugelassen // Rechtsrahmen stellt besseren Patientenschutz, transparente Informationen und Nachverfolgbarkeit von Daten sicher // Weltweit über 4 Millionen NGS-Patiententests in den Bereichen Onkologie und Erbkrankheiten mit QIAGEN Clinical Insight Interpret durchgeführt
GlobeNewswire Inc. • 2d ago
News Product / Services Announcement
QIAGEN erhält FDA-Zulassung für syndromischen QIAstat-Dx-Test zur schnellen und präzisen Diagnose von Atemwegserkrankungen
QIAstat-Dx Respiratory Panel Plus ist für genaue Diagnose von Atemwegsinfektionen konzipiert und ermöglicht auch Erkennung von Ko-Infektionen // Panel liefert Ergebnisse in etwa einer Stunde bei weniger als einer Minute aktiver Arbeitszeit und bietet leicht ablesbare Cycle-Threshold (Ct)-Werte sowie Amplifikationskurven // QIAGEN arbeitet an der Erweiterung des QIAstat-Dx Testmenüs in den USA; die Zulassung eines Magen-Darm-Panels wird aktuell von der FDA geprüft QIAstat-Dx Respiratory Panel Plus ist für genaue Diagnose von Atemwegsinfektionen konzipiert und ermöglicht auch Erkennung von Ko-Infektionen // Panel liefert Ergebnisse in etwa einer Stunde bei weniger als einer Minute aktiver Arbeitszeit und bietet leicht ablesbare Cycle-Threshold (Ct)-Werte sowie Amplifikationskurven // QIAGEN arbeitet an der Erweiterung des QIAstat-Dx Testmenüs in den USA; die Zulassung eines Magen-Darm-Panels wird aktuell von der FDA geprüft
GlobeNewswire Inc. • 3d ago
Stocks Company Announcement
QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results
QIAstat-Dx Respiratory Panel Plus designed for accurate diagnosis of respiratory infections, enabling detection of co-infections // Panel generates results in about one hour with less than one minute of hands-on time; offers easy access to Ct values and amplification curves // QIAGEN working on expanding QIAstat-Dx testing menu in the U.S., with a Gastrointestinal Panel currently under FDA review QIAstat-Dx Respiratory Panel Plus designed for accurate diagnosis of respiratory infections, enabling detection of co-infections // Panel generates results in about one hour with less than one minute of hands-on time; offers easy access to Ct values and amplification curves // QIAGEN working on expanding QIAstat-Dx testing menu in the U.S., with a Gastrointestinal Panel currently under FDA review
GlobeNewswire Inc. • 3d ago
Stocks Company Announcement
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 // Net sales at CER of $462 million ahead of outlook for at least $455 million CER and adj. diluted EPS of $0.47 CER ahead of $0.44 CER outlook // Excluding COVID-19 product groups, net sales decline 1% CER // Diagnostics sales +5% CER on double-digit CER growth in QuantiFERON and QIAstat‑Dx // 25.7% adjusted operating income margin on efficiency gains vs. 25.6% in Q1 2023 // Strong operating cash flow rises 85% to $133 million vs. Q1 2023 // 2024 outlook reaffirmed for at least $2.0 billion CER net sales and adj. diluted EPS of at least $2.10 CER Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 // Net sales at CER of $462 million ahead of outlook for at least $455 million CER and adj. diluted EPS of $0.47 CER ahead of $0.44 CER outlook // Excluding COVID-19 product groups, net sales decline 1% CER // Diagnostics sales +5% CER on double-digit CER growth in QuantiFERON and QIAstat‑Dx // 25.7% adjusted operating income margin on efficiency gains vs. 25.6% in Q1 2023 // Strong operating cash flow rises 85% to $133 million vs. Q1 2023 // 2024 outlook reaffirmed for at least $2.0 billion CER net sales and adj. diluted EPS of at least $2.10 CER
GlobeNewswire Inc. • 2w ago
Stocks Earnings Releases and Operating Results
QIAGEN übertrifft Prognosen für das erste Quartal 2024 und bleibt auf Kurs, die Jahresziele 2024 zu erreichen
Q1 2024: Konzernumsatz von $459 Mio. (-5% bei tatsächlichen Kursen; -5% bei konstanten Wechselkursen, CER); verwässerter Gewinn je Aktie von $0,36; bereinigter verwässerter Gewinn je Aktie von $0,46 // Konzernumsatz bei konstanten Wechselkursen (CER) von $462 Mio. übertrifft Prognose von mindestens $455 Mio. (CER); bereinigter verwässerter Gewinn je Aktie von $0,47 (CER) übertrifft Prognose von mindestens $0,44 CER // Ohne COVID-Produktgruppen sinkt Umsatz um 1% (CER) // Diagnostik-Umsätze steigen um 5% CER aufgrund zweistelliger CER-Zuwächse bei QuantiFERON und QIAstat-Dx // Bereinigte operative Marge steigt aufgrund von Effizienzsteigerungen von 25,6% (Q1 2023) auf 25,7% // Starker operativer Cashflow steigt im Vergleich zu Q1 2023 um 85% auf $133 Mio. // Prognose für 2024 bekräftigt: Konzernumsatz von mindestens $2,0 Mrd. (CER); bereinigter verwässerter Gewinn je Aktie von mindestens $2,10 (CER)
GlobeNewswire Inc. • 2w ago
Stocks Company Announcement
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
Launch of QIAseq xHYB Mycobacterium tuberculosis Panel for research use, enabling culture-free whole genome sequencing from complex samples // Panel significantly accelerates TB outbreak tracking and supports detection and management of antimicrobial resistance, critical needs in TB surveillance and control // Building upon success of leading diagnostics test QuantiFERON-TB Gold Plus as QIAGEN extends portfolio for TB management and control amid globally rising incidence rates Launch of QIAseq xHYB Mycobacterium tuberculosis Panel for research use, enabling culture-free whole genome sequencing from complex samples // Panel significantly accelerates TB outbreak tracking and supports detection and management of antimicrobial resistance, critical needs in TB surveillance and control // Building upon success of leading diagnostics test QuantiFERON-TB Gold Plus as QIAGEN extends portfolio for TB management and control amid globally rising incidence rates
GlobeNewswire Inc. • 3w ago
News Product / Services Announcement
QIAGEN erweitert Tuberkulose-Portfolio: Neues NGS-Panel unterstützt Echtzeit-Überwachung und Bekämpfung antimikrobieller Resistenzen
QIAseq xHYB Mycobacterium tuberculosis Panel zu Forschungszwecken ermöglicht kulturfreies Whole Genome Sequencing komplexer Proben // Panel beschleunigt Nachverfolgung von TB-Ausbrüchen und unterstützt Erkennung und Management antimikrobieller Resistenzen – entscheidende Faktoren bei der TB-Überwachung und -Kontrolle // QIAGEN baut auf Erfolg des führenden diagnostischen Tests QuantiFERON-TB Gold Plus auf und erweitert Portfolio für TB-Management und -Kontrolle angesichts weltweit steigender Inzidenzraten QIAseq xHYB Mycobacterium tuberculosis Panel zu Forschungszwecken ermöglicht kulturfreies Whole Genome Sequencing komplexer Proben // Panel beschleunigt Nachverfolgung von TB-Ausbrüchen und unterstützt Erkennung und Management antimikrobieller Resistenzen – entscheidende Faktoren bei der TB-Überwachung und -Kontrolle // QIAGEN baut auf Erfolg des führenden diagnostischen Tests QuantiFERON-TB Gold Plus auf und erweitert Portfolio für TB-Management und -Kontrolle angesichts weltweit steigender Inzidenzraten
GlobeNewswire Inc. • 3w ago
Stocks Company Announcement
QIAGEN N.V. to release results for Q1 2024 and hold webcast
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024.
GlobeNewswire Inc. • 1mo ago
News Product / Services Announcement
QIAGEN stärkt Portfolio für Krebsforschung und präsentiert Produktneuheiten auf dem Jahrestreffen der American Association for Cancer Research
Neue QIAcuity dPCR PanCancer Kits können gleichzeitig seltene Mutationen von EGFR- und BRAF-Genen erkennen und dabei Probenmaterial, Zeit und Kosten einsparen // Neues QIAseq Targeted RNA-seq Panel for T-cell-Receptor ermöglicht zielgerichtetes Next-Generation-Sequencing von T-Zell-Rezeptoren mit höherer Genauigkeit und Sensitivität // PAXgene® Urine Liquid Biopsy Set wird nicht-invasive Probenentnahme sowie Stabilisierung zellfreier DNA und damit Fortschritte in urinbasierter Flüssigbiopsie ermöglichen Neue QIAcuity dPCR PanCancer Kits können gleichzeitig seltene Mutationen von EGFR- und BRAF-Genen erkennen und dabei Probenmaterial, Zeit und Kosten einsparen // Neues QIAseq Targeted RNA-seq Panel for T-cell-Receptor ermöglicht zielgerichtetes Next-Generation-Sequencing von T-Zell-Rezeptoren mit höherer Genauigkeit und Sensitivität // PAXgene® Urine Liquid Biopsy Set wird nicht-invasive Probenentnahme sowie Stabilisierung zellfreier DNA und damit Fortschritte in urinbasierter Flüssigbiopsie ermöglichen
GlobeNewswire Inc. • 1mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT